Shares of Nanobiotix jumped 7.3% to $41.78 on July 10 as investors continued digesting eye-catching Phase 2 results for the company's radiation-boosting nanoparticle therapy in advanced lung cancer — data first presented nearly two months ago but still fueling follow-through buying.
An 86% Response Rate That Turns Heads — From Just Seven Patients. Among seven patients who completed treatment, the overall response rate was 85.7%, with a complete response rate of 57.1% and a disease control rate of 100%.
These initial outcomes suggest deeper and potentially more durable responses than typically seen with current standard-of-care chemoradiation, where complete responses are usually below 5%. Those numbers are striking, but the sample size demands extreme caution. The company explicitly warns these preliminary results from a very small cohort should not be relied on to predict future outcomes.
J&J Is Footing the Bill — and the Milestone Checks Could Be Enormous. In 2023, Nanobiotix signed a license agreement for the global co-development and commercialization of its therapy with Janssen, a Johnson & Johnson company. J&J now sponsors and runs both the lung cancer trial and the pivotal Phase 3 head-and-neck study, shielding Nanobiotix from most trial costs. Nanobiotix is eligible for up to $200 million in milestones from J&J tied to head and neck and lung programs — payments triggered only if development and regulatory goals are met. Nanobiotix completed a follow-on offering in May 2026 for roughly €86 million in gross proceeds , extending its cash runway to 2029.
The Stock Is Pricing In a Huge Market Before Proof Exists. The NSCLC treatment market reached $22 billion in 2025 and is projected to hit $36.5 billion by 2030. Yet Nanobiotix has no approved product in this space and generates just $32.6 million in trailing revenue against a roughly $1.9 billion market capitalization — a price-to-sales ratio above 50. The stock has traded as low as $3.12 over the past year, meaning today's price already reflects enormous optimism.
A Faster Path to Answers — If the Science Holds. An FDA-accepted protocol amendment to the Phase 3 head-and-neck trial removes a planned interim analysis and shifts to an earlier final readout , potentially accelerating Nanobiotix's first shot at regulatory approval. Lung cancer data from the randomized Part 2 of the trial will be the real test. Until those larger, controlled results arrive, investors are making a billion-dollar bet on seven patients and a partnership with pharma's biggest checkbook.